NasdaqGS - Delayed Quote USD

Nautilus Biotechnology, Inc. (NAUT)

2.4900 +0.1300 (+5.51%)
At close: April 26 at 4:00 PM EDT
2.4600 -0.03 (-1.20%)
After hours: April 26 at 5:48 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Sujal M. Patel Co-Founder, CEO, President, Secretary & Director 827.24k -- 1975
Dr. Parag Mallick Ph.D. Co-Founder, Chief Scientist & Director 562.8k -- 1978
Ms. Anna Mowry CFO & Treasurer 519.21k -- 1984
Ms. Mary E. Godwin Senior Vice President of Operations -- -- 1959
Mr. Matthew B. Murphy ESQ. General Counsel 382.64k -- 1965
Mr. Chris Blessington Vice President of Corporate Marketing & Communications -- -- --
Ms. Gwen E. Weld Chief People Officer 390.97k -- 1958
Mr. Nick A. Nelson Chief Business Officer & Senior VP of Business Development -- -- 1984
Dr. Subra Sankar Ph.D. Senior Vice President of Product Development 38.47k -- 1960

Nautilus Biotechnology, Inc.

2701 Eastlake Avenue East
Seattle, WA 98102
United States
206 333 2001 https://www.nautilus.bio
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
167

Description

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Corporate Governance

Nautilus Biotechnology, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 8; Board: 5; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • Mar 04, 2024
    CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
    See Full Filing
  • Feb 28, 2024
    8-K: Corporate Changes & Voting Matters
    See Full Filing
  • Dec 14, 2023
    8-K: Corporate Changes & Voting Matters
    See Full Filing
  • Nov 17, 2023
    SC 13D/A: Tender Offer/Acquisition Reports
    See Full Filing
  • Oct 31, 2023
    8-K: Corporate Changes & Voting Matters
    See Full Filing

Upcoming Events

Apr 30, 2024
Nautilus Biotechnology, Inc. Earnings Call

Related Tickers

SEER Seer, Inc.
1.9100
+9.14%
 
QSI Quantum-Si incorporated
1.6500
+2.48%
 
LABP Landos Biopharma, Inc.
22.31
-0.18%
 
688222.SS HitGen Inc.
12.98
+3.02%
 
CUE Cue Biopharma, Inc.
1.3650
-3.19%
 
DRMAW Dermata Therapeutics, Inc.
0.0095
+3.26%
 
ELVAF Evolva Holding SA
1.1000
0.00%
 
HVO.IR hVIVO plc
0.3200
0.00%
 
BNTX.VI BioNTech SE
82.30
+1.98%
 
SCPH scPharmaceuticals Inc.
4.4900
+3.22%